abstract this study aimed to investigate the efficacy and safety of drug eluting beads transarterial chemoembolization (deb-tace) treatment in barcelona clinic liver cancer (bclc) stage c liver cancer patients. in 39 patients with bclc stage c liver cancer, after the first cycle of deb-tace,2 (5.1%) and 24 (61.5%) patients achieved complete response (cr) and partial response (pr) to give an overall objective response rate (orr) of 66.7%. with respect to the second cycle of therapy, the orr was higher in patients receiving deb-tace compared with ctace (57.1% vs 11.1%). post first cycle of deb-tacetreatment,the percentages of abnormal albumin (alb), total protein (tp), total bilirubin (tbil) and alanine aminotransferase (alt) worsened at 1 week and recovered at 1 month. the number of patients with abnormal aspartate aminotransferase (ast) did not increase at 1 week but elevated at 1 month. after the second cycle of deb-tace or ctace treatment,no difference was observed between ctace and deb-tace in terms of all adverse events (aes) at all visits, and most of the aes did not change after the second cycle in both groups. the most common aes after the first and second treatment cycle were pain,fever, and nausea/vomiting. these results demonstrate that deb-tace offers patients with bclc stage c liver cancer with a clinically active short-term treatment that is safe and relatively well-tolerated.
摘要 本研究旨在探讨药物洗脱微球经动脉化疗栓塞(deb-tace)治疗巴塞罗那 (bclc)c期肝癌患者的疗效和安全性。在39例bclc分期c期肝癌患者中，经deb-tace第一周期治疗后，2例(5.1%)和24例(61.5%)患者分别获得完全缓解(cr)和部分缓解(pr)，总客观有效率(orr)为66.7%，第二周期治疗采用ctace或deb-tace，deb-tace治疗orr明显高于ctace(57.1%和11.1%)。deb-tace第一周期治疗后，白蛋白(alb)、总蛋白(tp)、总胆红素(tbil)和丙氨酸转氨酶(alt)在1周时出现恶化，1个月后恢复正常。天冬氨酸转氨酶(ast)异常患者1周时无增加，1个月时升高。在第二周期的deb-tace或ctace治疗后，两种治疗方式的所有不良事件(aes)均无差异，两组在第二个周期治疗后，大部分aes没有变化。两周期治疗后最常见的不良事件是疼痛、发烧和恶心呕吐。这些结果表明，deb-tace为巴塞罗那c期肝癌患者提供了一种临床上有效的短期治疗方案，具有良好的安全性及耐受性。